Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.040
-0.060 (-1.94%)
At close: Jan 30, 2026, 4:00 PM EST
3.115
+0.075 (2.47%)
After-hours: Jan 30, 2026, 6:12 PM EST
Anixa Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
101.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Oct 31, 2025 | - | - | - |
| Oct 31, 2024 | - | - | - |
| Oct 31, 2023 | 210.00K | - | - |
| Oct 31, 2022 | - | - | - |
| Oct 31, 2021 | 512.00K | - | - |
| Oct 31, 2020 | - | - | - |
| Oct 31, 2019 | 250.00K | -862.50K | -77.53% |
| Oct 31, 2018 | 1.11M | 750.00K | 206.90% |
| Oct 31, 2017 | 362.50K | 62.50K | 20.83% |
| Oct 31, 2016 | 300.00K | -8.96M | -96.76% |
| Oct 31, 2015 | 9.26M | 5.59M | 152.36% |
| Oct 31, 2014 | 3.67M | 3.28M | 843.12% |
| Oct 31, 2013 | 388.85K | -551.16K | -58.63% |
| Oct 31, 2012 | 940.01K | -63.18K | -6.30% |
| Oct 31, 2011 | 1.00M | 272.52K | 37.30% |
| Oct 31, 2010 | 730.68K | -325.12K | -30.79% |
| Oct 31, 2009 | 1.06M | -1.01M | -48.83% |
| Oct 31, 2008 | 2.06M | 1.58M | 323.77% |
| Oct 31, 2007 | 486.85K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 106.83M |
| Fortress Biotech | 62.30M |
| Champions Oncology | 58.42M |
| Seer, Inc. | 16.38M |
| Coya Therapeutics | 3.99M |
| Cibus | 3.79M |
| Artiva Biotherapeutics | 251.00K |
ANIX News
- 4 days ago - Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology - PRNewsWire
- 9 days ago - Water Tower Research Publishes Initiation of Coverage Report on Anixa Biosciences, Inc., “Anixa's T-Cell Innovations Show Breakthrough Potential in Solid Tumors” - TheNewswire
- 6 weeks ago - Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic - PRNewsWire
- 7 weeks ago - Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants - PRNewsWire
- 7 weeks ago - Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 - PRNewsWire
- 2 months ago - Anixa Biosciences, Inc. (ANIX) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs Transcript - Seeking Alpha
- 2 months ago - Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization - PRNewsWire
- 2 months ago - Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat - GlobeNewsWire